Health-related Quality of Life in Patients with CLDN18.2-positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Results from the SPOTLIGHT and GLOW Clinical Trials

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2024 Aug 15

PMID 39146670

Authors

F Lordick

E Van Cutsem

K Shitara

R-H Xu

J A Ajani

M A Shah

M Oh

A Ganguli

L Chang

S Rhoten

P Bhattacharya

M Matsangou

J W Park

R Pophale

R Ranganath

Y-K Kang

Affiliations

Soon will be listed here.

Abstract

Background: First-line zolbetuximab plus chemotherapy (SPOTLIGHT, mFOLFOX6; GLOW, CAPOX) significantly improved progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy in patients with human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors were claudin 18 isoform 2-positive in the phase III SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies. We present patient-reported outcomes (PROs) from these studies.

Materials And Methods: Health-related quality of life (HRQoL) was measured in the full analysis sets using the European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients Core Questionnaire (QLQ-C30) and Oesophago-Gastric Module (QLQ-OG25), Global Pain, and 5-level EQ-5D (EQ-5D-5L) questionnaires. Analyses focused on key PRO domains: global health status (GHS)/QoL, physical functioning, abdominal pain and discomfort, and nausea/vomiting. Least squares mean (LSM) changes from baseline and time to first definitive deterioration (TTDD) were evaluated combined across SPOTLIGHT and GLOW and for individual studies. Time to confirmed deterioration (TTCD) was evaluated independently for SPOTLIGHT and GLOW.

Results: The combined analysis set included 1072 patients (zolbetuximab plus chemotherapy, 537; placebo plus chemotherapy, 535). Compliance rates were similar between treatment arms. Similar trends were observed in the zolbetuximab versus placebo arms for LSM changes from baseline in key PRO domains, with no clinically meaningful deterioration. Nausea/vomiting worsened during the first few zolbetuximab cycles but later returned to baseline levels. Overall TTCD and TTDD results were similar between arms in both studies.

Conclusions: Patients in SPOTLIGHT and GLOW maintained measured HRQoL relative to baseline when treated with first-line zolbetuximab added to chemotherapy. Zolbetuximab plus chemotherapy improved PFS and OS without negatively affecting HRQoL in key PRO domains compared with placebo plus chemotherapy.

Citing Articles

Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis.

Yakuwa E, Shoji Y, Oizumi T, Kobayashi Y, Motoishi T, Katagiri T In Vivo. 2025; 39(2):951-960.

PMID: 40010971 PMC: 11884467. DOI: 10.21873/invivo.13900.

Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.

Li H, Zhu Z, Sun Y, Yuan C, Wang M, Wang N World J Gastroenterol. 2024; 30(40):4354-4366.

PMID: 39494097 PMC: 11525865. DOI: 10.3748/wjg.v30.i40.4354.

Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives.

Lordick F, Rha S, Muro K, Yong W, Obermannova R Cancers (Basel). 2024; 16(19).

PMID: 39409957 PMC: 11475804. DOI: 10.3390/cancers16193337.

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases.

Du F, Xie Y, Wu S, Ji M, Dong B, Zhu C J Hepatocell Carcinoma. 2024; 11:1801-1821.

PMID: 39345937 PMC: 11439345. DOI: 10.2147/JHC.S483861.

References

Shitara K, Kawazoe A, Hirakawa A, Nakanishi Y, Furuki S, Fukuda M . Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. Cancer Sci. 2022; 114(4):1606-1615. PMC: 10067400. DOI: 10.1111/cas.15684. View

Lordick F, Al-Batran S, Ganguli A, Morlock R, Sahin U, Tureci O . Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. Gastric Cancer. 2021; 24(3):721-730. PMC: 8064997. DOI: 10.1007/s10120-020-01153-6. View

Satoh T, Bang Y, Gotovkin E, Hamamoto Y, Kang Y, Moiseyenko V . Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014; 19(7):712-9. PMC: 4077451. DOI: 10.1634/theoncologist.2014-0058. View

Niimi T, Nagashima K, Ward J, Minoo P, Zimonjic D, Popescu N . claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001; 21(21):7380-90. PMC: 99911. DOI: 10.1128/MCB.21.21.7380-7390.2001. View

Casamayor M, Morlock R, Maeda H, Ajani J . Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2019; 12:883. PMC: 6345079. DOI: 10.3332/ecancer.2018.883. View

Shitara K, Ajani J, Moehler M, Garrido M, Gallardo C, Shen L . Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022; 603(7903):942-948. PMC: 8967713. DOI: 10.1038/s41586-022-04508-4. View

Shah M, Kennedy E, Alarcon-Rozas A, Alcindor T, Bartley A, Malowany A . Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol. 2023; 41(7):1470-1491. DOI: 10.1200/JCO.22.02331. View

Wang F, Zhang X, Li Y, Tang L, Qu X, Ying J . The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021; 41(8):747-795. PMC: 8360643. DOI: 10.1002/cac2.12193. View

Smyth E, Nilsson M, Grabsch H, van Grieken N, Lordick F . Gastric cancer. Lancet. 2020; 396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5. View

10.

van Kleef J, Ter Veer E, van den Boorn H, Schokker S, Ngai L, Prins M . Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2019; 112(1):12-29. DOI: 10.1093/jnci/djz133. View

11.

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G . Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(10):1005-1020. DOI: 10.1016/j.annonc.2022.07.004. View

12.

Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M . Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med. 2021; 11(11). PMC: 8624955. DOI: 10.3390/jpm11111095. View

13.

Sawada N . Tight junction-related human diseases. Pathol Int. 2013; 63(1):1-12. PMC: 7168075. DOI: 10.1111/pin.12021. View

14.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

15.

Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Tureci O . Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol. 2023; 149(9):5937-5950. PMC: 10356865. DOI: 10.1007/s00432-022-04459-3. View

16.

Apicella M, Corso S, Giordano S . Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017; 8(34):57654-57669. PMC: 5593674. DOI: 10.18632/oncotarget.14825. View

17.

Shah M, Shitara K, Ajani J, Bang Y, Enzinger P, Ilson D . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023; 29(8):2133-2141. PMC: 10427418. DOI: 10.1038/s41591-023-02465-7. View

18.

. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2022; 26(1):1-25. DOI: 10.1007/s10120-022-01331-8. View

19.

Huemer F, Weiss L, Regitnig P, Winder T, Hartmann B, Thaler J . Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry. J Clin Med. 2020; 9(4). PMC: 7230156. DOI: 10.3390/jcm9040935. View

20.

Moehler M, Xiao H, Blum S, Elimova E, Cella D, Shitara K . Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023; 41(35):5388-5399. PMC: 10713185. DOI: 10.1200/JCO.23.00170. View